Publicacións en colaboración con investigadores/as de Hospital Universitario de la Princesa (38)

2021

  1. HLA–B*08 Identified as the Most Prominently Associated Major Histocompatibility Complex Locus for Anti–Carbamylated Protein Antibody–Positive/Anti–Cyclic Citrullinated Peptide–Negative Rheumatoid Arthritis

    Arthritis and Rheumatology, Vol. 73, Núm. 6, pp. 963-969

  2. Role of MUC1 rs4072037 polymorphism and serum KL-6 levels in patients with antisynthetase syndrome

    Scientific Reports, Vol. 11, Núm. 1

  3. Tocilizumab in refractory giant cell arteritis. Monotherapy versus combined therapy with conventional immunosuppressive drugs. Observational multicenter study of 134 patients

    Seminars in Arthritis and Rheumatism, Vol. 51, Núm. 2, pp. 387-394

2020

  1. A predominant involvement of the triple seropositive patients and others with rheumatoid factor in the association of smoking with rheumatoid arthritis

    Scientific Reports, Vol. 10, Núm. 1

  2. Influence of MUC5B gene on antisynthetase syndrome

    Scientific Reports, Vol. 10, Núm. 1

  3. Publisher Correction: A predominant involvement of the triple seropositive patients and others with rheumatoid factor in the association of smoking with rheumatoid arthritis (Scientific Reports, (2020), 10, 1, (3355), 10.1038/s41598-020-60305-x)

    Scientific Reports

  4. Tocilizumab in giant cell arteritis: differences between the GiACTA trial and a multicentre series of patients from the clinical practice

    Clinical and experimental rheumatology, Vol. 38, Núm. 2, pp. 112-119

2019

  1. Identification of a 3′-Untranslated Genetic Variant of RARB Associated With Carotid Intima-Media Thickness in Rheumatoid Arthritis: A Genome-Wide Association Study

    Arthritis and Rheumatology, Vol. 71, Núm. 3, pp. 351-360

  2. Specific Association of HLA–DRB1*03 With Anti–Carbamylated Protein Antibodies in Patients With Rheumatoid Arthritis

    Arthritis and Rheumatology, Vol. 71, Núm. 3, pp. 331-339

  3. Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice

    Seminars in Arthritis and Rheumatism, Vol. 49, Núm. 1, pp. 126-135

2018

  1. Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients

    Seminars in Arthritis and Rheumatism, Vol. 48, Núm. 1, pp. 22-27

  2. Evaluation of a clinical pharmacogenetics model to predict methotrexate response in patients with rheumatoid arthritis

    Pharmacogenomics Journal, Vol. 18, Núm. 4, pp. 539-545

  3. Persistence and adverse events of biological treatment in adult patients with juvenile idiopathic arthritis: Results from BIOBADASER

    Arthritis Research and Therapy, Vol. 20, Núm. 1

  4. Replication study of polymorphisms associated with response to methotrexate in patients with rheumatoid arthritis

    Scientific Reports, Vol. 8, Núm. 1

2016

  1. Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review

    Rheumatology International, Vol. 36, Núm. 8, pp. 1043-1063

  2. Independent candidate serum protein biomarkers of response to adalimumab and to infliximab in rheumatoid arthritis: An exploratory study

    PLoS ONE, Vol. 11, Núm. 4

2015

  1. Actualización 2014 del Documento de Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en la artritis reumatoide

    Reumatologia Clinica, Vol. 11, Núm. 5, pp. 279-294

  2. Patterns of use and dosing of tocilizumab in the treatment of patients with rheumatoid arthritis in routine clinical practice: the ACT-LIFE study

    Rheumatology International, Vol. 35, Núm. 9, pp. 1525-1534

  3. Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients

    Seminars in Arthritis and Rheumatism, Vol. 44, Núm. 6, pp. 717-723

  4. Variability in the prescription of non-biologic disease-modifying antirheumatic drugs for the treatment of spondyloarthritis in Spain

    Seminars in Arthritis and Rheumatism, Vol. 44, Núm. 6, pp. 633-640